NVIDIA Corp. (0R1I)
London Exchange · UK · prices in USD · close of 15 Oct 2026
Key indicators
| Last close | USD 214.35 |
|---|---|
| 52-week range | 140.22 – 243.37 |
| Return, 1 month / 3 months | −0.3% / +5.8% |
| Return, 1 year / 3 years | +17.4% / +405.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 38 |
| Volatility (1 year) | 35.7% |
| Worst drawdown (1 year) | -19.6% |
| Average daily value traded | 205.63M USD |
| Dividend yield | 0.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
NVIDIA designs processors and related software for computing and graphics. Its products include graphics chips for gaming and professional visualisation, accelerators and networking equipment for data centres, and platforms for artificial intelligence and high-performance computing. Customers include gamers, cloud service providers, enterprises, researchers and automotive manufacturers. The company is based in Santa Clara, California, and sells its products in markets around the world.
NVIDIA Corp. trades under the code 0R1I on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
NVIDIA Corp. (0R1I) trades on the London Exchange in UK. It last closed at USD 214.35 on 15 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 574 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 17.4% and over the last three months it rose 5.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.6% | ||
| From 52-week high | -11.2% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.8% | ||
| 6-month return | 6.9% | ||
| 12-month return, skipping the last month | 17.7% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.6% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 205.63M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 59 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 0.1% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −9.2% |
|---|---|
| 1 month | −0.3% |
| 3 months | +5.8% |
| 6 months | +6.9% |
| 1 year | +17.4% |
| 3 years | +405.9% |
| 5 years | +874.8% |
Signals
| 50-day / 200-day average | 224.01 / 203.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.16 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | USD 0.2500 |
| 10 Mar 2026 | USD 0.0100 |
| 3 Dec 2025 | USD 0.0100 |
| 10 Sep 2025 | USD 0.0100 |
| 10 Jun 2025 | USD 0.0100 |
| 11 Mar 2025 | USD 0.0100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.